Celiac data persuade Takeda to commit to Cour’s tolerance-inducing therapy

Now that Cour has demonstrated clinical proof of concept, Takeda has exercised its option to license the company’s first-in-class celiac disease therapy that induces tolerance.

On Tuesday at the United European Gastroenterology Week meeting in Barcelona, Cour Pharmaceutical Development Co. Inc. showed that TAK-101 (CNP-101) met the primary endpoint in a Phase IIa trial for the disease, an autoimmune disorder in which ingestion of the allergen gluten triggers small intestinal inflammation and epithelial lining damage...